• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Racial Ethn Health Disparities . Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Labor

tetano

Editor, Senior Moderator
J Racial Ethn Health Disparities


. 2020 Nov 23.
doi: 10.1007/s40615-020-00918-0. Online ahead of print.
Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California


Jason Yamaki[SUP] 1 2 [/SUP], Harry Peled[SUP] 3 [/SUP], Sajen Mathews[SUP] 3 [/SUP], David Park[SUP] 3 [/SUP], Mina Firoozi[SUP] 3 [/SUP], Kim Smith[SUP] 3 [/SUP], Lee Nguyen[SUP] 4 5 [/SUP]



Affiliations

Abstract

Introduction: The severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) has infected more than 20 million people worldwide, and the spread is most prevalent in the USA, where California had accounted over 240,000 cases in the initial 5 months of the pandemic. To estimate the number of infected persons in our community, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection.
Methods: This cross-sectional study evaluated the presence of immunoglobulin G, antibody for SARS-CoV-2 during the time period of July 15, 2020, to July 27, 2020. Testing was done on serum samples from patients who had visited affiliated outpatient clinics or our emergency department. Additionally, we collected age, gender, ethnicity, race, and location of testing.
Results: Eight hundred sixty-five tests were included in the study. The outpatient clinics cohort accounted for 56% of results and emergency department (ED) contributed 44%. The positive percentage of SARS-CoV-2 test was 9.4% (95% CI: 0.08-0.12). The positivity rates of the outpatient (5.6%) and ED (14.2%) setting differed. The prevalence of SARS-CoV-2 IgG was greatest in those that identified as Hispanic/Latino, 18.1% versus 13.4% in other groups. Specifically compared to the non-Hispanic/Latino population, the prevalence was significantly higher, with a relative risk of 2.73 (95% CI: 1.8-4.1), p < 0.0001.
Conclusion: The low antibody positivity rate in the community indicates the need for a vaccine. The Hispanic/Latino patient population should be considered for increased education on preventing transmission and acquisition of COVID-19 as well as being considered as a priority for vaccination once a vaccine is available.

Keywords: COVID-19; Immunoglobulin G; SARS-CoV-2.
 
Back
Top Bottom